Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant radiotherapy plus tislelizumab after radical surgery for upper tract urothelial carcinoma
ChiCTR2500096861Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in upper tract urothelial carcinoma (UTUC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Disease-Free Survival. Started Feb 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on ChiCTR2500096861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096861.